Form 8-K · Current Report · Filed 2026-06-08
Ionis Pharmaceuticals Appoints Ludwig Hantson to Board of Directors
Ionis Pharmaceuticals, Inc. announced on June 4, 2026, the appointment of Ludwig N. Hantson, Ph.D., to its Board of Directors, effective immediately following the company's 2026 Annual Meeting of Stockholders. Dr. Hantson brings over 30 years of leadership experience in the biopharmaceutical industry, including serving as CEO and board member of Alexion and president of Baxter Bioscience. His appointment is expected to provide strategic and operational expertise as Ionis advances its commercial medicines and innovative pipeline.
- Filer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Accession
- 0001140361-26-024407
- CIK
- 0000874015
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$74.48
Next session
+0.1%
Since filing
-30.5%
Latest close
$51.77
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IONS reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, IONS insiders reported 89 Form 4 transactions — net selling of $11.4M.
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Never miss another IONS filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.